Medical Condition News

RSS

Exposure to 'white' LED light suppresses melatonin production

Exposure to the light of white LED bulbs, it turns out, suppresses melatonin 5 times more than exposure to the light of High Pressure Sodium bulbs that give off an orange-yellow light. "Just as there are regulations and standards for 'classic' pollutants, there should also be regulations and rules for the pollution stemming from artificial light at night," says Prof. Abraham Haim of the University of Haifa.

12 Sep 2011

Sanofi's Lyxumia achieves primary efficacy endpoint in study of patients uncontrolled on metformin

Sanofi announced today that Lyxumia (lixisenatide), a once-daily GLP-1 receptor agonist under development for type 2 diabetes, achieved its primary efficacy endpoint of significant HbA1c reduction vs. placebo in patients uncontrolled on metformin.

12 Sep 2011

CEO Roundtable on Cancer bestows Gold Standard accreditation to Memorial Sloan-Kettering

Memorial Sloan-Kettering Cancer Center has received CEO Cancer Gold Standard accreditation, recognizing the center's commitment to reducing cancer risk by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment for their own employees and their covered family members, as well as the patients whom they serve.

12 Sep 2011

Health Canada approves Merus Labs' advanced wound care product, Collexa

Merus Labs International Inc. is pleased to announce that Health Canada has approved its advanced wound care product Collexa. Collexa is exclusively licensed to Merus Labs by Innocoll for sales and distribution in Canada.

12 Sep 2011

Tensha raises $15 million in Series A financing to advance bromodomains for cancer

Tensha Therapeutics announced today that it has raised $15 million in a Series A financing to advance the development of small molecule bromodomain inhibitors for the treatment of cancer and other conditions by regulating the transcription of disease-associated genes.

12 Sep 2011

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.

12 Sep 2011

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Alchemia Limited, today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC). Two patients have received their first doses of therapy. This investigator sponsored trial is being conducted at Monash Cancer Centre, Southern Health and Peninsula Oncology Centre in Melbourne, Victoria.

12 Sep 2011

Rug Doctor launches new Anti-Allergen Carpet Cleaner

Just in time for indoor allergy season, Rug Doctor, the manufacturer of the most convenient do-it-yourself hot water extraction carpet cleaning machines and products, has introduced a new Anti-Allergen Carpet Cleaner.

12 Sep 2011

Genentech submits NDA to FDA for vismodegib to treat advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking sales and marketing approval for vismodegib to treat people with advanced basal cell carcinoma (BCC), which includes metastatic and locally advanced BCC for whom surgery is inappropriate.

12 Sep 2011

FDA clears Fujifilm's Aspire HD breast imaging system

Breast Imaging facilities looking for increased diagnostic confidence in mammography screening can now benefit from the exceptional image quality of the Aspire HD Full Field Digital Mammography (FFDM) system from FUJIFILM Medical Systems U.S.A., Inc. Now FDA 510(k) cleared, the Aspire HD provides image clarity that enables extraordinary detail of potential abnormalities that not only assists in more accurate and reliable diagnoses, but also results in enhanced clinician productivity.

12 Sep 2011

InterMune to launch Esbriet for German patients with IPF

InterMune, Inc. today announced that Esbriet will be offered to patients in Germany beginning September 15, 2011. This will mark the first time Esbriet will be commercially available in Europe since it was approved by the European Commission in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), a devastating and fatal lung disease.

12 Sep 2011

Genentech submits vismodegib NDA to FDA for treatment of advanced basal cell carcinoma

Genentech, a member of the Roche Group, today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

12 Sep 2011

IsoRay receives FDA clearance for GliaSite radiation therapy system to treat brain cancer

IsoRay, Inc. announced today that the FDA has cleared its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer.

12 Sep 2011

Researchers identify glucokinase triggers beta cell regeneration in pancreas

Researchers at the Hebrew University of Jerusalem have identified the key signal that prompts production of insulin-producing beta cells in the pancreas -- a breakthrough discovery that may ultimately help researchers find ways to restore or increase beta cell function in people with type 1 diabetes.

12 Sep 2011

Spinifex announces new data from EMA401 pre-clinical study on diabetic neuropathy

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces the presentation of new data from a study of EMA401 in a model of diabetic neuropathy.

12 Sep 2011

Heart attack patients with psoriasis more likely to die from cardiovascular disease

Heart attack patients with psoriasis are 26 per cent more likely to die from cardiovascular disease, or suffer from recurrent heart attacks or strokes, and are 18 per cent more likely to die from all causes than those without the inflammatory skin disease.

12 Sep 2011

PHT announces availability of eDHP-18 QoL questionnaire on all ePRO collection modalities

PHT Corporation announced today the availability of the electronic version of the DHP-18 (Diabetes Health Profile) Quality of Life (QoL) questionnaire on all of its electronic patient reported outcome (ePRO) collection modalities - smartphone, tablet and Web. PHT is the global pacesetter in PRO and ePRO solutions that maximize the collection of high-quality data from clinical trial patients to improve clinical trial efficiencies.

12 Sep 2011

Lund University professor receives Fernström Foundation Nordic Prize for brain cell transplants

This year's Fernström Foundation Nordic Prize, with prize money of SEK 1 million, goes to Professor Anders Björklund from Lund University, Sweden. He is a neurology researcher focusing on neurodegenerative diseases, diseases in which the nerve cells die. Professor Björklund's research group is trying to develop customised stem cells to treat Parkinson's disease.

12 Sep 2011

New improved method can help doctors diagnose early-stage osteoarthritis

A new method is set to help doctors diagnose osteoarthritis at such an early stage that it will be possible to delay the progression of the disease by many years, or maybe even stop it entirely.

12 Sep 2011

EpiCept announces FDA's feedback on Ceplene clinical development for AML

EpiCept Corporation today announced that at a recent meeting with the U.S. Food and Drug Administration (FDA) the Company was provided more definitive guidance regarding the clinical development of Ceplene, the Company's lead product administered with interleukin-2 (IL-2) for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first complete remission.

12 Sep 2011

Medical Condition News

Exposure to 'white' LED light suppresses melatonin production

Sanofi's Lyxumia achieves primary efficacy endpoint in study of patients uncontrolled on metformin

CEO Roundtable on Cancer bestows Gold Standard accreditation to Memorial Sloan-Kettering

Health Canada approves Merus Labs' advanced wound care product, Collexa

Tensha raises $15 million in Series A financing to advance bromodomains for cancer

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Rug Doctor launches new Anti-Allergen Carpet Cleaner

Genentech submits NDA to FDA for vismodegib to treat advanced basal cell carcinoma

FDA clears Fujifilm's Aspire HD breast imaging system

InterMune to launch Esbriet for German patients with IPF

Genentech submits vismodegib NDA to FDA for treatment of advanced basal cell carcinoma

IsoRay receives FDA clearance for GliaSite radiation therapy system to treat brain cancer

Researchers identify glucokinase triggers beta cell regeneration in pancreas

Spinifex announces new data from EMA401 pre-clinical study on diabetic neuropathy

Heart attack patients with psoriasis more likely to die from cardiovascular disease

PHT announces availability of eDHP-18 QoL questionnaire on all ePRO collection modalities

Lund University professor receives Fernström Foundation Nordic Prize for brain cell transplants

New improved method can help doctors diagnose early-stage osteoarthritis

EpiCept announces FDA's feedback on Ceplene clinical development for AML

Microphysiological systems in drug discovery

Considerations for taking ASO discovery programs into animal models

Neurofilament light as a translational biomarker

Latest News